Glucocorticoids, inflammation and the perinatal lung

Area of Science:

• Neonatal Medicine
• Fetal Development
• Pulmonology

Background:

• Subclinical chorioamnionitis is common in preterm infants (<30 weeks gestation).
• Maternal glucocorticoid treatment is standard for inducing fetal lung maturation.
• Proinflammatory fetal exposure can cause injury but also promote lung maturation.

Purpose of the Study:

• To explore the dual effects of antenatal glucocorticoids and inflammation on preterm fetal lung development.
• To identify future strategies for safer fetal lung maturation.
• To highlight risks associated with current treatments.

Main Methods:

• Review of existing literature on antenatal glucocorticoids and chorioamnionitis.
• Analysis of the impact of inflammation on fetal lung maturation.
• Examination of glucocorticoid effects on surfactant system, structural maturation, and alveolarization.

Main Results:

• Both glucocorticoids and inflammation modulate lung development pathways.
• These factors induce the surfactant system and structural maturation.
• Alveolarization is inhibited by both antenatal glucocorticoids and inflammation.

Conclusions:

• Antenatal glucocorticoids and inflammation have complex, sometimes opposing, effects on fetal lung development.
• Future research should focus on developing safer strategies to mature the preterm fetus.
• Risks include adverse interactions from repetitive glucocorticoid exposure and undetected fetal inflammation.